IPO Boutique

PhaseBio Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on PhaseBio Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
PhaseBio PharmaceuticalsPHAS -
NASDAQ
$12.00-$14.00 $5.00 $5.009.2 million10/18/2018
Citigroup, Cowen, Stifel
Co-Manager(s):
Needham & Company
Health Care
Filing(s):

Filed 2018-09-21
Terms Added 2018-10-05



PhaseBio Pharmaceuticals Quote & Chart - Click for current quote - PHAS

About PhaseBio Pharmaceuticals (adapted from PhaseBio Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "PHAS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved